Nezam Afdhal

Nezam Afdhal is a leading hepatologist who has made foundational contributions to the clinical management of viral hepatitis and its progression to cirrhosis and HCC. His research defined the relationship between liver fibrosis stage and HCC risk, informing current surveillance guidelines. He played key roles in the clinical development of direct-acting antivirals for HCV and demonstrated that HCV eradication substantially reduces but does not eliminate HCC risk in cirrhotic patients. His work continues to refine HCC risk stratification in the post-antiviral treatment era.